High Burden of Obesity and Low Rates of Weight Loss Pharmacotherapy in Inflammatory Bowel Disease: 10-Year Trend.
epidemiology
inflammatory bowel disease
metabolic syndrome
obesity
Journal
Crohn's & colitis 360
ISSN: 2631-827X
Titre abrégé: Crohns Colitis 360
Pays: England
ID NLM: 101752188
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
01
08
2022
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
The prevalence of obesity and inflammatory bowel disease (IBD) has increased in the last decade. There is a paucity of data on the recent trend of obesity and the utilization of anti-obesity pharmacotherapy in IBD. We aimed to use a population-level database to analyze their trends. A retrospective analysis of population-level data from 2010 to 2019 was performed among individuals ≥18 years of age using a commercial database, IBM Explorys. The prevalence and trends of obesity, diabetes mellitus type 2 (DM2), essential hypertension, dyslipidemia and/or hyperlipidemia, sleep apnea, and anti-obesity pharmacotherapy were studied. Univariate analysis using chi-square test and trend analysis using the Cochrane Armitage test were performed. Among 39 717 520 adults, 37.3% of IBD patients have a diagnosis of obesity (Crohn's disease 36.9% vs ulcerative colitis 38.5%, With obesity being a harbinger for metabolic syndrome, the increase in obesity in IBD patients was accompanied by a concomitant increase in the diseases associated with obesity in the past decade. However, this alarming rise in obesity was accompanied by a disproportionately small increase in anti-obesity pharmacotherapy similar to general population.
Sections du résumé
Background
UNASSIGNED
The prevalence of obesity and inflammatory bowel disease (IBD) has increased in the last decade. There is a paucity of data on the recent trend of obesity and the utilization of anti-obesity pharmacotherapy in IBD. We aimed to use a population-level database to analyze their trends.
Methods
UNASSIGNED
A retrospective analysis of population-level data from 2010 to 2019 was performed among individuals ≥18 years of age using a commercial database, IBM Explorys. The prevalence and trends of obesity, diabetes mellitus type 2 (DM2), essential hypertension, dyslipidemia and/or hyperlipidemia, sleep apnea, and anti-obesity pharmacotherapy were studied. Univariate analysis using chi-square test and trend analysis using the Cochrane Armitage test were performed.
Results
UNASSIGNED
Among 39 717 520 adults, 37.3% of IBD patients have a diagnosis of obesity (Crohn's disease 36.9% vs ulcerative colitis 38.5%,
Conclusions
UNASSIGNED
With obesity being a harbinger for metabolic syndrome, the increase in obesity in IBD patients was accompanied by a concomitant increase in the diseases associated with obesity in the past decade. However, this alarming rise in obesity was accompanied by a disproportionately small increase in anti-obesity pharmacotherapy similar to general population.
Identifiants
pubmed: 36937138
doi: 10.1093/crocol/otad007
pii: otad007
pmc: PMC10022715
doi:
Types de publication
Journal Article
Langues
eng
Pagination
otad007Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
Déclaration de conflit d'intérêts
None declared.
Références
Am J Gastroenterol. 2020 Jun;115(6):934-940
pubmed: 32496740
Clin Nutr. 2022 Oct;41(10):2364-2405
pubmed: 35970666
JAMA Health Forum. 2022 Mar 1;3(3):e220608
pubmed: 36218869
J Clin Med. 2019 Mar 11;8(3):
pubmed: 30862129
Inflamm Bowel Dis. 2019 May 4;25(6):1080-1087
pubmed: 30500938
J Am Heart Assoc. 2017 Aug 2;6(8):
pubmed: 28768646
Am J Gastroenterol. 2018 May;113(5):694-701
pubmed: 29535417
Gastroenterol Clin North Am. 2016 Dec;45(4):663-672
pubmed: 27837780
Prev Chronic Dis. 2019 Apr 11;16:E46
pubmed: 30974071
Obesity (Silver Spring). 2022 Aug;30(8):1573-1578
pubmed: 35894076
Gut. 2013 May;62(5):689-94
pubmed: 22961677
Medicine (Baltimore). 2020 Jul 2;99(27):e21016
pubmed: 32629722
Inflamm Bowel Dis. 2015 Feb;21(2):361-8
pubmed: 25563694
J Am Coll Surg. 2013 May;216(5):986-96
pubmed: 23523148
Gastroenterology. 2022 Nov;163(5):1198-1225
pubmed: 36273831
Inflamm Bowel Dis. 2013 Dec;19(13):2949-56
pubmed: 23945182
Int J Obes (Lond). 2018 Mar;42(3):495-500
pubmed: 29151591
Inflamm Bowel Dis. 2020 Jan 1;26(1):1-10
pubmed: 31112238
Inflamm Bowel Dis. 2013 Apr;19(5):1059-64
pubmed: 23448789
J Hypertens. 2012 Sep;30(9):1775-81
pubmed: 22796713
Inflamm Bowel Dis. 2015 Dec;21(12):2857-63
pubmed: 26241001
Dig Dis Sci. 2015 Aug;60(8):2436-45
pubmed: 25799938
Am J Gastroenterol. 2011 Apr;106(4):741-7
pubmed: 21386828
Aliment Pharmacol Ther. 2018 Jun;47(11):1472-1479
pubmed: 29665045
J Am Med Inform Assoc. 2010 Sep-Oct;17(5):602-7
pubmed: 20819871
Am J Physiol Gastrointest Liver Physiol. 2015 Apr 1;308(7):G591-604
pubmed: 25591865
Lancet Diabetes Endocrinol. 2018 Mar;6(3):237-248
pubmed: 28919062
Blood Press. 2018 Aug;27(4):240-246
pubmed: 29790793
Clin Gastroenterol Hepatol. 2014 Mar;12(3):382-93.e1: quiz e22
pubmed: 23978350
Clin Gastroenterol Hepatol. 2019 Mar;17(4):709-718.e7
pubmed: 30012429
Gastroenterol Hepatol (N Y). 2016 Nov;12(11):704-707
pubmed: 28035199
Inflamm Bowel Dis. 2020 Aug 20;26(9):1436-1442
pubmed: 31944255
JAMA. 2018 Apr 24;319(16):1723-1725
pubmed: 29570750
Endocr Pract. 2018 Apr;24(4):321-328
pubmed: 29561192
Am J Gastroenterol. 1998 Dec;93(12):2411-9
pubmed: 9860401
Obes Sci Pract. 2016 Sep;2(3):266-271
pubmed: 27708843
Obesity (Silver Spring). 2019 Dec;27(12):1975-1981
pubmed: 31603630
Metabolism. 2019 Mar;92:170-192
pubmed: 30391259
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):110-121
pubmed: 27899815
Proc (Bayl Univ Med Cent). 2019 Feb 1;32(1):14-17
pubmed: 30956572
Metab Syndr Relat Disord. 2020 Feb;18(1):31-38
pubmed: 31750766
Obes Surg. 2021 Mar;31(3):1105-1112
pubmed: 32986169